Department of Medicinal Chemistry

Daniel A. Harki, Ph.D.

COP - Image - Size 3 - Harki_Dan
    Medicinal Chemistry
    Assistant Professor
  • B.A.
    West Virginia University (1999)
  • Ph.D.
    The Pennsylvania State University (2005)
  • Postdoc
    California Institute of Technology (2005-2009)
  • synthetic - organic and medicinal chemistry
  • chemical biology
  • nucleic acids
  • cancer stem cells
  • 2-139 Cancer & Cardiovascular Research Building
  • University of Minnesota
    College of Pharmacy
    Department of Medicinal Chemistry
    2231 Sixth Street SE #2-139
    Minneapolis, MN 55455

About Daniel A. Harki, Ph.D.

Research in the Harki laboratory focuses on the design, synthesis and biophysical characterization of small molecules that influence cellular function. Applications for these molecules range from anticancer drug discovery to new tools for modern biotechnology research. Our core science is organic chemistry. However, we use techniques of modern molecular biology, genetics, and genomics to probe the biological activities of the compounds we synthesize. The following projects are currently underway:

Targeting Cancer Stem Cells with Small Molecules:
This research aims to develop chemical probes to study cancer stem cell (CSC) biology, and to develop small molecules that target CSCs.

Light-regulated Nucleotides and Oligonucleotides:
We are developing novel nucleosides whose hybridization properties can be controlled photochemically.

Development of Antibodies to Detect Topoisomerase-DNA Complexes:
In collaboration with Professor Scott Kaufmann (Mayo Clinic) we are developing theragnostic antibodies to detect topoisomerase-DNA covalent complexes.

Small Molecule Inhibitors of APOBEC3 Proteins:
In collaboration with Professor Reuben Harris (UMN) we are developing small molecule inhibitors of APOBEC3 cytosine deaminases for applications in biotechnology and human medicine.

California Tobacco-Related Disease Research Program, Postdoctoral Fellowship 2007-09
Friedreich's Ataxia Research Alliance, Postdoctoral Fellowship 2006-07
American Heart Association, Predoctoral Fellowship 2002-05
Phi Beta Kappa, Alpha of West Virginia, West Virginia University 1999

Harki DA, Kaufmann SH, Perkins AL (2015) “Methods and materials for assessing enzyme-nucleic acid complexes” U.S. Serial No. 62/186,816, filed June 30, 2015.

Harki DA, Harris RS, Perkins AL, Olson ME, Abate-Pella D, Li M (2014) “Small molecule inhibitors of APOBEC3G and APOBEC3B” U.S. Serial No. 61/926,751, filed January 14, 2014; converted January 13, 2015 (PCT/US2015/11209).

Harris RS, Harki DA, Perkins-Harki AL, Carpenter MA and Li M (2010) “Cytosine deaminase modulators for enhancement of DNA transfection” U.S. Serial No. 61/410,482, filed November 5, 2010; converted November 3, 2011 (PCT/US2011/059178).


Published Works

Olson ME, Abate-Pella D, Perkins AL, Li M, Carpenter MA, Rathore A, Harris RS and Harki DA. Oxidative reactivities of 2-furylquinolines: Ubiquitous scaffolds in common high-throughput screening libraries. J. Med. Chem. 2015, 58, 7419-7430

Kempema AM, Widen JC, Hexum JK, Andrews TW, Wang D, Rathe SK, Meece FA, Noble K, Sachs Z, Largaespada DA and Harki DA. Synthesis and antileukemic activities of C1-C10 modified parthenolide analogues. Bioorg. Med. Chem. 2015, 23, 4737-4745

Hexum JK, Becker CM, Kempema AM, Ohlfest JR, Largaespada DA and Harki DA. Parthenolide prodrug LC-1 slows growth of intracranial glioma. Bioorg. Med. Chem. Lett. 2015, 25, 2493-2495

Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA and Dehm SM. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget 2015, 6, 3811-3824


  • ©2010 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on September 28, 2015